{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:03:56Z","timestamp":1787022236214,"version":"build-2736575974"},"reference-count":143,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1378\/chest.126.3_suppl.576s","type":"journal-article","created":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T18:47:46Z","timestamp":1095792466000},"page":"576S-599S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"special_numbering":"S","title":["Antithrombotic Therapy During Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"126","author":[{"given":"Jeffrey J.","family":"Popma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Grines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.126.3_suppl.576S_bib1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/0735-1097(92)90631-V","article-title":"Lesion morphology and coronary angioplasty: current experience and analysis","volume":"19","author":"Myler","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/01.CIR.83.3.927","article-title":"Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management and follow-up","volume":"83","author":"de Feyter","year":"1991","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/01.CIR.82.3.739","article-title":"Incidence and consequences of periprocedural occlusion: the 1985\u20131986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry","volume":"82","author":"Detre","year":"1990","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/0735-1097(92)90272-O","article-title":"Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile","volume":"19","author":"Lincoff","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0002-8703(96)90231-8","article-title":"Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients","volume":"132","author":"Altmann","year":"1996","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9149(97)89324-1","article-title":"Effects of endoluminal coronary stents on the frequency of coronary artery bypass grafting after unsuccessful percutaneous transluminal coronary vascularization","volume":"77","author":"Lindsay","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib8","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib9","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJM198806303182603","article-title":"Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty","volume":"318","author":"Schwartz","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.76.1.125","article-title":"Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty","volume":"76","author":"Barnathan","year":"1987","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/0002-9149(90)90804-A","article-title":"Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty","volume":"65","author":"Lembo","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib12","series-title":"Antiplatelet therapy in percutaneous coronary intervention.","first-page":"5","author":"Cho","year":"2002"},{"key":"10.1378\/chest.126.3_suppl.576S_bib13","first-page":"236A","article-title":"A randomized trial of aspirin in PTCA: effect of high versus low dose aspirin on major complications and restenosis [abstract]","volume":"11","author":"Mufson","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.69.4.721","article-title":"Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study","volume":"69","author":"Thornton","year":"1984","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib15","doi-asserted-by":"crossref","first-page":"48B","DOI":"10.1016\/0002-9149(87)90484-X","article-title":"The Frankfurt experience in restenosis after coronary angioplasty","volume":"60","author":"Bussman","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib16","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/0002-9149(91)90402-7","article-title":"Effects of low-dose aspirin on restenosis after coronary angioplasty","volume":"68","author":"Taylor","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib17","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/0735-1097(91)90489-V","volume":"18","author":"Wallentin","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib18","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1378\/chest.126.3_suppl.576S_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-129-5-199809010-00009","article-title":"The antiplatelet effects of ticlopidine and clopidogrel","volume":"129","author":"Sharis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1055\/s-0037-1615238","article-title":"The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit","volume":"80","author":"Herbert","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.576S_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM199408253310802","article-title":"A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators","volume":"331","author":"Fischman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease","volume":"8","author":"Serruys","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib25","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib26","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.CIR.0000086347.31341.F9","article-title":"Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study","volume":"108","author":"Mehran","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib27","first-page":"150","article-title":"Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent: the ANTARES study","volume":"55","author":"Bartorelli","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.126.3_suppl.576S_bib28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/archinte.160.9.1370","article-title":"Hemolytic uremic syndrome associated with clopidogrel: a case report","volume":"160","author":"Moy","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib29","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","article-title":"Thrombotic thrombocytopenic purpura associated with clopidogrel","volume":"342","author":"Bennett","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib30","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0735-1097(99)00442-8","article-title":"Clopidogrel versus ticlopidine after intracoronary stent placement","volume":"34","author":"Berger","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib31","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/01.CIR.99.18.2364","article-title":"Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation","volume":"99","author":"Moussa","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib32","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0735-1097(99)00443-X","article-title":"Clopidogrel as adjunctive antiplatelet therapy during coronary stenting","volume":"34","author":"Mishkel","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib34","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.CIR.101.6.590","article-title":"A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents","volume":"101","author":"Muller","year":"2000","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1067\/mhj.2002.121929","volume":"143","author":"Berger","year":"2002","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(99)00005-3","article-title":"Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin","volume":"83","author":"Wilson","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0735-1097(03)00622-3","article-title":"Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting","volume":"42","author":"Wilson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.576S_bib40","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"Suppl IV","key":"10.1378\/chest.126.3_suppl.576S_bib41","first-page":"374","article-title":"Optimal duration of pretreatment with clopidogrel prior to PCI: data from the CREDO trial","volume":"108","author":"Steinhubl","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1067\/mhj.2002.119372","article-title":"Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation","volume":"143","author":"Seyfarth","year":"2002","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000006871","article-title":"Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients","volume":"91","author":"Schaefer","year":"1999","journal-title":"Cardiology"},{"key":"10.1378\/chest.126.3_suppl.576S_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1067\/mai.2000.104571","article-title":"Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema","volume":"105","author":"Wong","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib46","first-page":"IV","article-title":"Antiplatelet agents are effective in reducing the immediate complications of PTCA: results of the ticlopidine multicenter trial [abstract]","volume":"76","author":"White","year":"1987","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib47","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(03)14462-5","article-title":"Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)","volume":"362","author":"Schofer","year":"2003","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.576S_bib49","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa032441","article-title":"A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease","volume":"350","author":"Stone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib51","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/01.CIR.0000086926.62288.A6","article-title":"Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions","volume":"108","author":"Colombo","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib52","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0149-2918(97)80058-6","article-title":"A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation","volume":"19","author":"Kunishima","year":"1997","journal-title":"Clin Ther"},{"key":"10.1378\/chest.126.3_suppl.576S_bib53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0002-9149(00)01001-8","article-title":"Effects of cilostazol on angiographic restenosis after coronary stent placement","volume":"86","author":"Park","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib54","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa021007","article-title":"A paclitaxel-eluting stent for the prevention of coronary restenosis","volume":"348","author":"Park","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1067\/mjh.2002.122874","article-title":"Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis","volume":"144","author":"Kamishirado","year":"2002","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0167-5273(01)00388-6","article-title":"Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine","volume":"78","author":"Tanabe","year":"2001","journal-title":"Int J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.100.1.21","article-title":"Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty","volume":"100","author":"Tsuchikane","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib58","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0735-1097(90)90648-9","article-title":"Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty","volume":"15","author":"Knudtson","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib59","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/01.CIR.84.4.1568","volume":"84","author":"Serruys","year":"1991","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib60","first-page":"50","article-title":"Sulotroban during and after coronary angioplasty: a double-blind, placebo controlled study","volume":"78","author":"Finci","year":"1989","journal-title":"Kardiologie"},{"key":"10.1378\/chest.126.3_suppl.576S_bib61","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0002-8703(91)90561-U","article-title":"Multi-hospital Eastern Atlantic restenosis trial II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty","volume":"122","author":"Savage","year":"1991","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib62","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/01.CIR.88.4.1588","article-title":"Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: a multicenter randomized double-blind placebo-controlled trial","volume":"88","author":"Serruys","year":"1993","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib63","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1067\/mhj.2003.176","article-title":"Sarpogrelate treatment reduces restenosis after coronary stenting","volume":"145","author":"Fujita","year":"2003","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/hrt.71.1.7","article-title":"Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial","volume":"71","author":"Gershlick","year":"1994","journal-title":"Br Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib65","first-page":"305","article-title":"Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty","volume":"37","author":"Darius","year":"1992","journal-title":"Agents Actions Suppl"},{"key":"10.1378\/chest.126.3_suppl.576S_bib66","first-page":"1689","article-title":"The EPILOG Investigators","volume":"336","author":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib67","first-page":"87","article-title":"The EPISTENT Investigators","volume":"352","author":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade: evaluation of platelet IIb\/IIIa inhibitor for stenting","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.576S_bib68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(94)90007-8","article-title":"Randomised trial of coronary intervention with antibody against platelet IIb\/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators","volume":"343","author":"Topol","year":"1994","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.576S_bib69","first-page":"I","article-title":"Synergy of stenting plus abciximab in diabetic patients: persistence through 1-year follow-up from EPISTENT [abstract]","volume":"100","author":"Marso","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib70","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1161\/01.CIR.0000018123.02672.C7","article-title":"Impact of different platelet glycoprotein IIb\/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up","volume":"105","author":"Roffi","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib71","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0735-1097(99)00329-0","article-title":"The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions","volume":"34","author":"Mathew","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib72","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0735-1097(97)00395-1","article-title":"\u201cRescue\u201d utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty","volume":"30","author":"Muhlestein","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib73","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0002-9149(03)00816-6","article-title":"Meta-analysis of survival with platelet glycoprotein IIb\/IIIa antagonists for percutaneous coronary interventions","volume":"92","author":"Kong","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib74","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II; Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.576S_bib75","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.576S_bib76","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1001\/jama.285.19.2468","article-title":"Platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial; a randomized controlled trial","volume":"285","author":"O'Shea","year":"2001","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.576S_bib77","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib78","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","volume":"96","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib79","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib80","first-page":"425","article-title":"A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban","volume":"52","author":"Simon","year":"2001","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.126.3_suppl.576S_bib81","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0002-9149(03)00024-9","article-title":"Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris","volume":"91","author":"Soffer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib82","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9149(01)02319-0","article-title":"Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions","volume":"89","author":"Kabbani","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib83","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1161\/01.CIR.0000029744.01096.1F","volume":"106","author":"Batchelor","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib84","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0002-9149(02)02892-8","article-title":"Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban","volume":"90","author":"Schneider","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib85","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJM199905273402103","article-title":"Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators","volume":"340","author":"Hamm","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib86","first-page":"436","article-title":"Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy","volume":"339","author":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes: The PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib87","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: a method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.576S_bib88","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1016\/S0735-1097(02)03019-X","article-title":"The thrombolysis in myocardial infarction risk score in unstable angina\/non-ST-segment elevation myocardial infarction","volume":"41","author":"Sabatine","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/euhj.2001.2738","article-title":"An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI Risk Score for UA\/NSTEMI in PRISM-PLUS","volume":"23","author":"Morrow","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib90","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.290.12.1593","article-title":"Evaluation of prolonged antithrombotic pretreatment (\u201ccooling-off\u201d strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial","volume":"290","author":"Neumann","year":"2003","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.576S_bib91","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib92","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib93","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib94","first-page":"497","article-title":"Platelet glycoprotein IIb\/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study","volume":"57","author":"Kaul","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.126.3_suppl.576S_bib95","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.4960170704","article-title":"The use of activated clotting times to monitor heparin therapy during and after interventional procedures","volume":"17","author":"Bowers","year":"1994","journal-title":"Clin Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib96","first-page":"260","article-title":"Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin","volume":"26","author":"Dougherty","year":"1992","journal-title":"Cathet Cardiovasc Diagn"},{"key":"10.1378\/chest.126.3_suppl.576S_bib97","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/01.CIR.93.4.667","article-title":"Relation between activated clotting time during angioplasty and abrupt closure","volume":"93","author":"Narins","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib98","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0735-1097(94)90590-8","article-title":"Relation between procedural activated clotting time and outcome after percutaneous transluminal coronary angioplasty","volume":"23","author":"Ferguson","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib99","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib100","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(97)00609-7","article-title":"Early ambulation after coronary angioplasty and stenting with six French guiding catheters and low-dose heparin","volume":"80","author":"Koch","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib101","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/oxfordjournals.eurheartj.a015308","article-title":"A randomized trial of a fixed high dose versus a low weight adjusted low dose of intravenous heparin during coronary angioplasty","volume":"18","author":"Boccara","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib102","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0002-8703(89)90612-1","article-title":"Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty","volume":"117","author":"Ellis","year":"1989","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib103","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/0735-1097(94)90101-5","article-title":"Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty","volume":"24","author":"Friedman","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib104","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/0735-1097(95)00277-4","article-title":"The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial: results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome","volume":"26","author":"Brack","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib105","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0002-8703(02)00131-X","article-title":"Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus","volume":"144","author":"Kereiakes","year":"2002","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib106","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0002-9149(99)00582-2","article-title":"Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris","volume":"84","author":"Rabah","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib107","first-page":"7A","article-title":"Anticoagulation requirements for coronary interventions and the role of low molecular weight heparins","volume":"11","author":"Grines","year":"1999","journal-title":"J Invasive Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib108","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0002-9149(02)02298-1","article-title":"Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes","volume":"89","author":"Brieger","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib109","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11886-002-0069-6","article-title":"Unfractionated versus fractionated heparin for percutaneous coronary intervention","volume":"4","author":"Arjomand","year":"2002","journal-title":"Curr Cardiol Rep"},{"key":"10.1378\/chest.126.3_suppl.576S_bib110","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0002-8703(03)00165-0","article-title":"Combining enoxaparin and glycoprotein IIb\/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study","volume":"146","author":"Ferguson","year":"2003","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib111","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1053\/euhj.1998.1054","article-title":"Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty: a comparison between treatment with reviparin and unfractionated heparin\/placebo (results of a substudy of the REDUCE trial)","volume":"19","author":"Preisack","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib112","first-page":"247","article-title":"Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes","volume":"14","author":"Miller","year":"2002","journal-title":"J Invasive Cardiol"},{"issue":"Suppl E","key":"10.1378\/chest.126.3_suppl.576S_bib113","first-page":"E14","article-title":"Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators","volume":"12","author":"Young","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib114","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mhj.2002.126115","article-title":"Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study","volume":"144","author":"Cohen","year":"2002","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0735-1097(02)02631-1","article-title":"Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study","volume":"41","author":"Bhatt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib116","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1067\/mhj.2001.113217","article-title":"Dalteparin in combination with abciximab during percutaneous coronary intervention","volume":"141","author":"Kereiakes","year":"2001","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib117","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/01.CIR.90.2.908","article-title":"Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) Trial","volume":"90","author":"Faxon","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib118","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1161\/01.CIR.96.10.3396","article-title":"Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale","volume":"96","author":"Lablanche","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib119","first-page":"160","article-title":"Fraxiparin for prevention of restenosis after percutaneous transluminal coronary angioplasty","volume":"1","author":"Amann","year":"1993","journal-title":"Semin Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.576S_bib120","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.289.7.903","article-title":"Should bivalirudin replace heparin during percutaneous coronary interventions?","volume":"289","author":"Antman","year":"2003","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.576S_bib121","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.576S_bib122","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","article-title":"Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)","volume":"143","author":"Lincoff","year":"2002","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib123","first-page":"177","article-title":"Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia","volume":"57","author":"Lewis","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.126.3_suppl.576S_bib124","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","article-title":"A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators","volume":"333","author":"Serruys","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib125","first-page":"346","article-title":"Bivalirudin in percutaneous coronary interventions and acute coronary syndromes: new concepts, new directions","volume":"1","author":"Shah","year":"1999","journal-title":"Curr Interv Cardiol Rep"},{"key":"10.1378\/chest.126.3_suppl.576S_bib126","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.576S_bib127","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study","volume":"142","author":"Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9149(98)00371-3","article-title":"Effect of direct thrombin inhibition with bivalirudin (hirulog) on restenosis after coronary angioplasty","volume":"82","author":"Burchenal","year":"1998","journal-title":"Am J Cardiol"},{"issue":"Suppl F","key":"10.1378\/chest.126.3_suppl.576S_bib129","first-page":"14F","article-title":"Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention","volume":"12","author":"Campbell","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib130","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0002-8703(99)70180-8","article-title":"Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study","volume":"138","author":"Machraoui","year":"1999","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib131","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/hrt.60.6.485","article-title":"Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty","volume":"60","author":"Urban","year":"1988","journal-title":"Br Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib132","first-page":"315","article-title":"Heparin and Coumadin versus acetylsalicylic acid for prevention of restenosis after coronary angioplasty","volume":"55","author":"Garachemani","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.126.3_suppl.576S_bib133","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mhj.2003.63","article-title":"A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: results of the 6-month angiographic substudy of the Balloon Angioplasty and Anticoagulation Study (BAAS)","volume":"145","author":"ten Berg","year":"2003","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib134","first-page":"462","article-title":"Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial","volume":"96","author":"Kastrati","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1067\/mhj.2000.108826","article-title":"Clopidogrel instead of ticlopidine after coronary stent placement: is the switch justified?","volume":"140","author":"Berger","year":"2000","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.576S_bib136","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Early and late effects of clopidogrel in patients with acute coronary syndromes","volume":"107","author":"Yusuf","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib137","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1161\/01.CIR.94.7.1553","article-title":"Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: the EMPAR Study","volume":"94","author":"Cairns","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib138","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0735-1097(96)00343-9","volume":"28","author":"Karsch","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1378\/chest.126.3_suppl.576S_bib139","first-page":"155","article-title":"First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty","volume":"19","author":"Schmid","year":"1993","journal-title":"Semin Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.576S_bib140","first-page":"723","article-title":"A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty","volume":"13","author":"Grassman","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib141","first-page":"272","article-title":"Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention","volume":"13","author":"Kereiakes","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"10.1378\/chest.126.3_suppl.576S_bib142","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","article-title":"Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris","volume":"103","author":"Collet","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.576S_bib143","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(02)02531-7","article-title":"A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention","volume":"40","author":"Choussat","year":"2002","journal-title":"J Am Coll Cardiol"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921531504X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921531504X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:00:36Z","timestamp":1757919636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236921531504X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":143,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S001236921531504X"],"URL":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.576s","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy During Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.576S","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}